Assessment of the Effects of a Daily Supplement 4Life Transfer Factor Vista Containing AREDS2 Formula on Skin Carotenoid Levels Using a Non-invasive Detection

Completed · Not applicable

Conditions studied: Skin Carotenoids

In brief

The goal of the clinical study is to evaluate the impact of daily use of a dietary supplement TF Vista containing AREDS2 formula ingredients, astaxanthin (Haematococcus pluvialis) microalgae, bilberry (Vaccinium myrtillus) fruit powder and black currant (Ribes nigrum) fruit powder organic on skin carotenoid levels over an 8-week period for a Cohort 1(n= 20 participants) and 12 weeks for a Cohort 2 (n= 4 participants). Results will be compared using two devices - the Veggie Meter and the Samsung Watch - both of which utilize reflection spectroscopy technology. For Cohort 2 (n = 4 participants), in addition to assessing skin carotenoid levels, the study will also evaluate changes in macular pigment optical density (MPOD) before and after supplementation.

Key facts

Study ID: NCT07513597
Run by: 4Life Research, LLC
People needed: 24
Starts: 2025-10-16
Expected to finish: 2026-02-14
Last updated by the study team: 2026-04-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Healthy subjects ≥ 18 years of age. Committed to maintain the same eating, exercise, and other lifestyle routines for the whole duration of the study.

You may not qualify if…

• Pregnant and/or lactating women or planning to become pregnant in the following 12 weeks.
Participants were not allowed to participate if they have a known allergy or adverse reaction to any of the ingredients in the study product.
Participants were not allowed to participate if they have used AREDS2 formula products over the past 6 months.

Where it is running

4Life Research — Sandy City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.